Change in Body Weight During Treatment of Advanced Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

264 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-01

Study Completion Date

2022-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancer (CRC) is a significant and growing health burden in Hong Kong. According to data from Hong Kong Cancer Registry, CRC ranked the first in incidence and the second in mortality, with around 5,000 new cases diagnosed and more than 2,000 cancer-related mortality in 2014. The investigators aim to evaluate the association between serial weight change during first line treatment and outcomes in patients with metastatic CRC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immune Checkpoints in Colorectal Cancer

NCT04051450

Colorectal Cancer

UNKNOWN

Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.

NCT06778382

Colorectal Neoplasms Malignant

RECRUITING PHASE2

Intra-operative Chemotherapy With 5-FU for Colorectal Cancer Patients Receiving Curative Resection: Efficacy and Safety

NCT01465451

Colorectal Cancer

UNKNOWN PHASE3

The Continuing Care Needs in Colorectal Cancer Patients in Different Stages

NCT00961129

Colorectal Cancer

UNKNOWN

PET-CT and Circulating Tumor Cells in Colorectal Cancer

NCT01163305

Colorectal Cancer Metastasis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Studies have suggested that exposure to a greater number of chemotherapeutic agents is associated with better survival in metastatic colorectal cancer.

Multiple factors might affect body weight during treatment. Cancer-related symptoms can impair quality of life and appetite. Cachexia syndrome affects around 50% of colon cancer patients and is characterized by cancer-induced catabolism with involuntary weight loss (fat and muscle), patients have increased lipolysis and change in skeletal muscle metabolism, including increased energy expenditure at rest and protein degradation, and decreased protein synthesis. Besides these disease factors, treatment related side effects are common causes of weight loss, such as inability to ingest or digest food effectively due to nausea, vomiting, and malaise. Based on these factors and the hypotheses between tumour control and weight gain, monitoring the serial weight change can have practical value.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer, Colorectal Chemotherapy Effect Weight Loss Prognosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

stage IV colorectal cancer

stage IV colorectal cancer on first line systemic treatment are observed for the trend of weight change and treatment outcomes

first line systemic treatment for colorectal cancer

Intervention Type DRUG

systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

first line systemic treatment for colorectal cancer

systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven adenocarcinoma of colorectal origin
* Stage IV disease with systemic treatment
* Estimated life expectancy \>3 months
* Adequate organ functions

Exclusion Criteria

* Eastern Cooperative Oncology Group performance status 3 or above
* Pregnancy
* Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS)
* Past medical history of another cancer

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No